Log in

NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, Forecast & News

-1.93 (-5.71 %)
(As of 02/25/2020 03:22 AM ET)
Today's Range
Now: $31.87
50-Day Range
MA: $28.84
52-Week Range
Now: $31.87
Volume1.40 million shs
Average Volume1.28 million shs
Market Capitalization$3.16 billion
P/E RatioN/A
Dividend YieldN/A
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:MNTA



Sales & Book Value

Annual Sales$75.59 million
Book Value$4.68 per share


Net Income$-176,060,000.00
Net Margins-361.66%


Market Cap$3.16 billion
Next Earnings Date2/26/2020 (Confirmed)

Receive MNTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MNTA and its competitors with MarketBeat's FREE daily newsletter.

Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its quarterly earnings results on Thursday, October, 31st. The biotechnology company reported ($0.59) EPS for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.09. The biotechnology company had revenue of $6.40 million for the quarter, compared to analysts' expectations of $5.24 million. Momenta Pharmaceuticals had a negative net margin of 361.66% and a negative return on equity of 59.82%. The business's quarterly revenue was down 57.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.65) earnings per share. View Momenta Pharmaceuticals' Earnings History.

When is Momenta Pharmaceuticals' next earnings date?

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Momenta Pharmaceuticals.

How can I listen to Momenta Pharmaceuticals' earnings call?

Momenta Pharmaceuticals will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for MNTA?

8 equities research analysts have issued 1-year price objectives for Momenta Pharmaceuticals' shares. Their forecasts range from $14.15 to $50.00. On average, they expect Momenta Pharmaceuticals' share price to reach $33.64 in the next year. This suggests a possible upside of 5.6% from the stock's current price. View Analyst Price Targets for Momenta Pharmaceuticals.

What is the consensus analysts' recommendation for Momenta Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Momenta Pharmaceuticals.

Has Momenta Pharmaceuticals been receiving favorable news coverage?

News articles about MNTA stock have trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Momenta Pharmaceuticals earned a daily sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Momenta Pharmaceuticals.

Who are some of Momenta Pharmaceuticals' key competitors?

What other stocks do shareholders of Momenta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Momenta Pharmaceuticals investors own include Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Mylan (MYL), Coherus Biosciences (CHRS), ImmunoGen (IMGN), Novavax (NVAX), Teva Pharmaceutical Industries (TEVA) and Halozyme Therapeutics (HALO).

Who are Momenta Pharmaceuticals' key executives?

Momenta Pharmaceuticals' management team includes the folowing people:
  • Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 59)
  • Dr. Ganesh Venkataraman Kaundinya, Co-Founder & Consultant (Age 52)
  • Dr. Santiago Arroyo, Chief Medical Officer & Sr. VP of Devel. (Age 59)
  • Mr. Bruce A. Leicher, Consultant (Age 63)
  • Mr. Scott M. Storer, Consultant

Who are Momenta Pharmaceuticals' major shareholders?

Momenta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (17.53%), State Street Corp (3.87%), Perceptive Advisors LLC (2.86%), Farallon Capital Management LLC (2.78%), Palo Alto Investors LP (1.70%) and Point72 Asset Management L.P. (1.64%). Company insiders that own Momenta Pharmaceuticals stock include Alejandra Carvajal, Anthony M Manning, Bruce Downey, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Ian Fier, Jo Ann Beltramello, Jose-Carlos Gutierrez-Ramos, Michelle Robertson, Santiago Arroyo and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.

Which major investors are selling Momenta Pharmaceuticals stock?

MNTA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Citigroup Inc., Peregrine Capital Management LLC, State of New Jersey Common Pension Fund D, Palo Alto Investors LP, Perceptive Advisors LLC and UBS Group AG. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Alejandra Carvajal, Anthony M Manning, Bruce Downey, Craig A Wheeler, Elizabeth Stoner, Ian Fier, Jo Ann Beltramello, Jose-Carlos Gutierrez-Ramos, Michelle Robertson, Santiago Arroyo and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.

Which major investors are buying Momenta Pharmaceuticals stock?

MNTA stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, FMR LLC, RA Capital Management L.P., Jennison Associates LLC, UBS Asset Management Americas Inc., AXA, Driehaus Capital Management LLC and State Street Corp. View Insider Buying and Selling for Momenta Pharmaceuticals.

How do I buy shares of Momenta Pharmaceuticals?

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Momenta Pharmaceuticals' stock price today?

One share of MNTA stock can currently be purchased for approximately $31.87.

How big of a company is Momenta Pharmaceuticals?

Momenta Pharmaceuticals has a market capitalization of $3.16 billion and generates $75.59 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. Momenta Pharmaceuticals employs 131 workers across the globe.View Additional Information About Momenta Pharmaceuticals.

What is Momenta Pharmaceuticals' official website?

The official website for Momenta Pharmaceuticals is http://www.momentapharma.com/.

How can I contact Momenta Pharmaceuticals?

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]

MarketBeat Community Rating for Momenta Pharmaceuticals (NASDAQ MNTA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  542 (Vote Outperform)
Underperform Votes:  552 (Vote Underperform)
Total Votes:  1,094
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: Pattern Day Trader

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel